Seagen

Shasqi Appoints Travis Biechele, Ph.D. as VP of Research to Lead Pipeline Development

Retrieved on: 
Monday, March 11, 2024
Pharmacology, Therapeutic index, Seagen, SAN, Patient, University, Spacecraft, MD, Neoplasm, CAPAC, ADC, Shasqi, Click chemistry, Pharmaceutical industry

SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.
  • Biechele has over two decades of experience in oncology research, with a focus on developing antibody-drug conjugates (ADCs), with both Seagen (now Pfizer) and Merck.
  • Shasqi's pipeline is composed of a range of tumor-targeted activators against validated antigen targets that are combined with protodrugs based on a range of validated payloads.
  • Prior to Merck, Biechele spent 10 years at Seagen (now Pfizer), where he played a pivotal role in the development of ADC technology.

Convergent Therapeutics Appoints Scott Myers as Chairman of its Board of Directors

Retrieved on: 
Monday, March 4, 2024
Acquisition, Cancer, Prostate, Entrepreneurship, Therapy, Seagen, ADHD, Convergent, Pharmaceutical industry

CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers, today announced the appointment of Scott Myers as Chairman of its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers, today announced the appointment of Scott Myers as Chairman of its Board of Directors.
  • "Speaking on behalf of Convergent's Board of Directors and our leadership team, I am delighted that Scott agreed to join our Board as Chair," said Dr. Philip Kantoff, Co-Founder and CEO of Convergent.
  • Mr. Myers currently serves as the Chairman of the Board of Dynavax Technologies, a commercial stage vaccine company.
  • Mr. Myers also serves as Chairman of the Board of Directors of Ironshore Pharmaceuticals, a private, commercial stage ADHD company.

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, University, Neoplasm, Lantern, Patient, Therapy, Research, Neurology, Glioblastoma, UC, Multimedia, Neuro, Brain, DIPG, Cancer, NCI, Starlight, ATRT, USC, Central nervous system, Seagen, Physician, CNS, Pharmaceutical industry

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D.

Key Points: 
  • Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D.
  • has joined Starlight as its Chief Medical Officer.
  • In his role, Dr. Chamberlain will apply his significant medical, clinical, and pharmaceutical development expertise to advance Starlight’s AI-enabled and accelerated drug development portfolio.
  • “Starlight, in collaboration with Lantern Pharma, is poised to advance its novel central nervous system (CNS) penetrant wholly synthetic acylfulvene, LP-184 (referred to as “STAR-001” for CNS indications), to target tumors in the brain.

Update: Annual Changes to the Nasdaq-100® Index

Retrieved on: 
Tuesday, December 12, 2023
TTWO, PFE, NDAQ, Acquisition, Seagen, Take-Two Interactive, Pfizer

NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX).

Key Points: 
  • NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX).
  • Per the announcement by Pfizer Inc. (NYSE: PFE), the pending acquisition of Seagen, Inc. (Nasdaq: SGEN) is expected to close on December 14, 2023.
  • The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.
  • For information about the company being added to the Nasdaq-100 Index® per this update, please visit the company website: Take-Two Interactive Software, Inc. – https://www.take2games.com/ .

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 16, 2023
Form 6-K, Neck, Medicare Part D, Safety, Therapy, Head, Colorectal cancer, Bank statement, Investment, Clinical trial, Patient, Research, LAVA, Part, Lung cancer, PSMA, Janssen, Exhibit, Vaccine, Pharmaceutical industry, Cryptocurrency, Seagen

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, today announced recent corporate highlights and financial results for the quarter ended September 30, 2023.

Key Points: 
  • UTRECHT, The Netherlands and PHILADELPHIA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, today announced recent corporate highlights and financial results for the quarter ended September 30, 2023.
  • Trial enrollment is progressing across 10 clinical trial sites in Europe and the United States.
  • The financial information provided below reflects changes made to previously issued consolidated financial statements to revise immaterial prior-period misstatements.
  • As of September 30, 2023, LAVA had cash, cash equivalents and investments totaling $104.6 million compared to cash, cash equivalents and investments of $132.9 million as of December 31, 2022.

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

Retrieved on: 
Friday, December 15, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Cisplatin, Carboplatin, NYSE, Food, Progression-free survival, Risk, Patient, PFS, Brentuximab vedotin, Death, PDUFA, OS, MRK, Pharmaceutical industry, Pfizer, Merck, Seagen

KEYTRUDA plus enfortumab vedotin reduced the risk of death by 53% (HR=0.47 [95% CI, 0.38-0.58]; p

Key Points: 
  • KEYTRUDA plus enfortumab vedotin reduced the risk of death by 53% (HR=0.47 [95% CI, 0.38-0.58]; p
  • Median OS was 31.5 months (95% CI, 25.4-not reached) for KEYTRUDA plus enfortumab vedotin versus 16.1 months (95% CI, 13.9-18.3) for platinum-based chemotherapy.
  • KEYTRUDA plus enfortumab vedotin reduced the risk of disease progression or death by 55% (HR=0.45 [95% CI, 0.38-0.54]; p
  • Median PFS was 12.5 months (95% CI, 10.4-16.6) for KEYTRUDA plus enfortumab vedotin versus 6.3 months (95% CI, 6.2-6.5) for platinum-based chemotherapy.

Pfizer Completes Acquisition of Seagen

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, Research, Policy, Acquisition, PFE, Spacecraft, LLP, Avelumab, Investment, ADC, Brentuximab vedotin, Antibody-drug conjugate, Protein engineering, Sullivan & Cromwell, Science, Centerview Partners, Oliver Cromwell, AACR, Cancer, Death, Financial toxicity, Communication, Federal Trade Commission, Growth, Guggenheim Partners, Inc., Arnold & Porter, Conjugation, Education, Pharmaceutical industry, Fine chemical, Pfizer, Seagen

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
  • Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
  • With the addition of Seagen, Pfizer’s Oncology pipeline has doubled in size with 60 programs spanning multiple modalities, including ADCs, small molecules, bispecifics and other immunotherapies.
  • “This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.

Pfizer Provides Full-Year 2024 Guidance

Retrieved on: 
Wednesday, December 13, 2023
Professional Services, Health, Finance, Banking, Pharmaceutical, Biotechnology, Research, Safety, Acquisition, Pediatrics, Overview, Federation, Annual report, Risk, COVID-19 vaccine, Clinical trial, Intellectual property, EPS, Formula, Vaccine, Messenger, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Omicron, Global Economic Symposium, GAAP, Analysis, BioNTech, MD, EST, Public, BNT162, Dive (Belgian band), Financial condition report, Publication, Result, Originality, Security (finance), Pharmaceutical industry, Risk management, Pfizer, Seagen

Financial guidance for Adjusted(5) diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023 or 2024.

Key Points: 
  • Financial guidance for Adjusted(5) diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023 or 2024.
  • As announced on December 12, 2023, Pfizer and Seagen have received all required regulatory approvals for the closing of the acquisition.
  • Pfizer expects to complete the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
  • Financial guidance for full-year 2024 reflects the following:
    Guidance for Adjusted(5) diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.75 billion shares, and assumes no share repurchases in 2024.

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, Pfizer, Research, Acquisition, NYSE, Policy, PFE, Hart–Scott–Rodino Antitrust Improvements Act, Avelumab, Patient, Science, Vaccine, Cancer, Communication, Federal Trade Commission, EST, Inc., AACR, Education, Pharmaceutical industry, Seagen

Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition.

Key Points: 
  • Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition.
  • Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
  • Pfizer also announces changes in its commercial organization to incorporate Seagen and improve focus, speed and quality of execution.
  • During the call Pfizer will discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance.

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

Retrieved on: 
Monday, December 11, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Doxorubicin, Safety, Toxicity, Rollcage Stage II, AVD, Progression-free survival, Progressive multifocal leukoencephalopathy, ADC, Febrile neutropenia, Brentuximab vedotin, Patient, Research and development, PFS, Bleomycin, DOR, PML, Hodgkin lymphoma, PD-1, CHL, Lymphoma, Vinblastine, Dacarbazine, Development, Nivolumab, Survival, Massachusetts General Hospital, ADCETRIS, Immunotherapy, Society, Inc., Hospital, Ima Hogg, Pharmaceutical industry, Vaccine, Medical device, Birth control, Seagen

This is the first time 12-month PFS results were presented for the treatment combination, which avoids use of vinblastine and bleomycin in patients with early stage cHL.

Key Points: 
  • This is the first time 12-month PFS results were presented for the treatment combination, which avoids use of vinblastine and bleomycin in patients with early stage cHL.
  • The PFS rate was 100% (95% CI: 100, 100) at 12 months and 97% (95% CI: 90.3, 99.1) at 18 months.
  • Among 56 efficacy-evaluable patients, 95% had an OR (95% CI: 85.1, 98.9) and 89% had a CR (95% CI: 78.1, 96.0).
  • The estimated PFS rate at 24 months was 88% (95% CI: 75.7, 94.6), with a median follow-up of 24.2 months (95% CI: 23.4, 26.9).